These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 1725922)

  • 41. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.
    Zhu D; Zhang Y; Barniak V; Bernfield L; Howell A; Zlotnick G
    Infect Immun; 2005 Oct; 73(10):6838-45. PubMed ID: 16177362
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design.
    Feavers IM; Fox AJ; Gray S; Jones DM; Maiden MC
    Clin Diagn Lab Immunol; 1996 Jul; 3(4):444-50. PubMed ID: 8807211
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune responses in humans and animals to meningococcal transferrin-binding proteins: implications for vaccine design.
    Ala'Aldeen DA; Stevenson P; Griffiths E; Gorringe AR; Irons LI; Robinson A; Hyde S; Borriello SP
    Infect Immun; 1994 Jul; 62(7):2984-90. PubMed ID: 8005685
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine.
    Rosenqvist E; Høiby EA; Wedege E; Bryn K; Kolberg J; Klem A; Rønnild E; Bjune G; Nøkleby H
    Infect Immun; 1995 Dec; 63(12):4642-52. PubMed ID: 7591118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of a second generation group B meningococcal vaccine.
    Frasch CE; Sacchi CT; Brandiolone MC; Vieiera VS; Leite LC
    NIPH Ann; 1991 Dec; 14(2):225-30; discussion 230-1. PubMed ID: 1812436
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunoblotting studies of vaccinee and patient sera from a Norwegian serogroup B meningococcal vaccination trial.
    Wedege E; Bjune G; Frøholm LO; Høiby EA; Rosenqvist E
    NIPH Ann; 1991 Dec; 14(2):183-4; discussion 185-6. PubMed ID: 1812431
    [No Abstract]   [Full Text] [Related]  

  • 47. Second generation meningococcal OMP-LPS vaccines.
    Poolman JT; van der Ley PA; Wiertz EJ; Hoogerhout P
    NIPH Ann; 1991 Dec; 14(2):233-41. PubMed ID: 1725922
    [No Abstract]   [Full Text] [Related]  

  • 48. Development of a meningococcal vaccine.
    Poolman JT
    Infect Agents Dis; 1995 Mar; 4(1):13-28. PubMed ID: 7728353
    [No Abstract]   [Full Text] [Related]  

  • 49. Polysaccharides and membrane vaccines.
    Poolman JT
    Adv Biotechnol Processes; 1990; 13():57-86. PubMed ID: 1970737
    [No Abstract]   [Full Text] [Related]  

  • 50. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 51. Vaccines against meningococcal meningitis: current status.
    Epidemiol Bull; 1994 Jul; 15(2):13-5. PubMed ID: 8086300
    [No Abstract]   [Full Text] [Related]  

  • 52. Production and control of Neisseria meningitidis vaccines.
    Frasch CE
    Adv Biotechnol Processes; 1990; 13():123-45. PubMed ID: 2110462
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.